CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 47.88 USD 3.43% Market Closed
Market Cap: 4.1B USD
Have any thoughts about
CRISPR Therapeutics AG?
Write Note

CRISPR Therapeutics AG
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CRISPR Therapeutics AG
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
CRISPR Therapeutics AG
NASDAQ:CRSP
Effect of Foreign Exchange Rates
$139k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Effect of Foreign Exchange Rates
$184k
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Effect of Foreign Exchange Rates
-CHf5.1m
CAGR 3-Years
N/A
CAGR 5-Years
-69%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Effect of Foreign Exchange Rates
-CHf2.4m
CAGR 3-Years
-31%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Effect of Foreign Exchange Rates
-CHf30k
CAGR 3-Years
N/A
CAGR 5-Years
50%
CAGR 10-Years
11%
Kuros Biosciences AG
SIX:KURN
Effect of Foreign Exchange Rates
CHf12k
CAGR 3-Years
N/A
CAGR 5-Years
-45%
CAGR 10-Years
N/A
No Stocks Found

CRISPR Therapeutics AG
Glance View

Market Cap
4.1B USD
Industry
Biotechnology

CRISPR Therapeutics AG operates as a gene editing company. The company is headquartered in Zug, Zug and currently employs 473 full-time employees. The company focuses on the development of transformative gene-based medicines for serious diseases. The firm develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The firm has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The firm has business operations in London and the United Kingdom, as well as research and development operations in the United States.

CRSP Intrinsic Value
119.73 USD
Undervaluation 60%
Intrinsic Value
Price

See Also

What is CRISPR Therapeutics AG's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
139k USD

Based on the financial report for Sep 30, 2024, CRISPR Therapeutics AG's Effect of Foreign Exchange Rates amounts to 139k USD.

What is CRISPR Therapeutics AG's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 1Y
39%

Over the last year, the Effect of Foreign Exchange Rates growth was 39%.

Back to Top